Erlotinib-13C6

(Synonyms: CP-358774-13C6; NSC 718781-13C6; OSI-774-13C6)

Erlotinib-13C6 (CP-358774-13C6) is the 13C-labeled Erlotinib (HY-50896). Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • No. CAS: 1211107-68-4
  • Fòrmula: C1613C6H23N3O4
  • Peso molecular:399.39
  • Almacenamiento:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Actividad biológica
  • Chemical Information
  • Protocolo
  • Pureza y Documentación
  • Referencias
  • Help & FAQs

Ver todos los productos específicos de isoformas EGFR

More

Ver todos los productos específicos de isoformas ERK

More

Ver todos los productos específicos de isoformas GSK-3

More
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00